Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Physiologically activated mammary fibroblasts promote postpartum mammary cancer
Qiuchen Guo, Jessica Minnier, Julja Burchard, Kami Chiotti, Paul Spellman, Pepper Schedin
Qiuchen Guo, Jessica Minnier, Julja Burchard, Kami Chiotti, Paul Spellman, Pepper Schedin
View: Text | PDF
Research Article Oncology

Physiologically activated mammary fibroblasts promote postpartum mammary cancer

  • Text
  • PDF
Abstract

Women diagnosed with breast cancer within 5 years of childbirth have poorer prognosis than nulliparous or pregnant women. Weaning-induced breast involution is implicated, as the collagen-rich, immunosuppressive microenvironment of the involuting mammary gland is tumor promotional in mice. To investigate the role of mammary fibroblasts, isolated mammary PDGFRα+ cells from nulliparous and postweaning mice were assessed for activation phenotype and protumorigenic function. Fibroblast activation during involution was evident by increased expression of fibrillar collagens, lysyl oxidase, Tgfb1, and Cxcl12 genes. The ability of mammary tumors to grow in an isogenic, orthotopic transplant model was increased when tumor cells were coinjected with involution-derived compared with nulliparous-derived mammary fibroblasts. Mammary tumors in the involution-fibroblast group had increased Ly6C+ monocytes at the tumor border, and decreased CD8+ T cell infiltration and tumor cell death. Ibuprofen treatment suppressed involution-fibroblast activation and tumor promotional capacity, concurrent with decreases in tumor Ly6C+ monocytes, and increases in intratumoral CD8+ T cell infiltration, granzyme levels, and tumor cell death. In total, our data identify a COX/prostaglandin E2 (PGE2)–dependent activated mammary fibroblast within the involuting mammary gland that displays protumorigenic, immunosuppressive activity, identifying fibroblasts as potential targets for the prevention and treatment of postpartum breast cancer.

Authors

Qiuchen Guo, Jessica Minnier, Julja Burchard, Kami Chiotti, Paul Spellman, Pepper Schedin

×

Figure 4

Prostaglandin E2 (PGE2) directly stimulates fibroblast collagen and cytokine expression but not cell elongation.

Options: View larger image (or click on image) Download as PowerPoint
Prostaglandin E2 (PGE2) directly stimulates fibroblast collagen and cyto...
(A) Col1a1, Mmp3, and Cxcl12 gene expression induced by 1 ng/ml PGE2 (1 PGE2) or 5 ng/ml PGE2 (5 PGE2) treatment, n = 4–8 per group. All gene expression data are normalized to Actb and then normalized to the control groups in each experiment. Gene expression data obtained from 4 to 8 independent experiments. (B) Mammary fibroblast morphology when cultured within floating collagen pads in the absence (right) and presence of 5 ng/ml PGE2. Scale bar: 100 μm. (C) Model of fibroblast-induced monocyte-derived cell migration assay setup. (D) Quantification of the number of monocyte-derived cells that migrated into collagen pads in Control (1 μg/ml mouse IgG1 isotype control), 1 PGE2 (1 ng/ml PGE2 with 1 μg/ml mouse IgG1 isotype control), and +anti-CXCL12 (1 ng/ml PGE2 with 1 μg/ml CXCL12-neutralizing antibody) conditions, with data normalized to control, n = 5/condition. Monocyte-derived cell migration assay was repeated 5 times. (E) Representative images of migrated monocyte-derived cells labeled with CFSE (green) fluorescent dye in Control, 1 PGE2, and 1 PGE2+anti-CXCL12 conditions as described in D. Scale bar: 200 μm. *P < 0.5, **P < 0.01 by matched 1-way ANOVA with Tukey correction on the raw data that are not normalized to control. Data represent mean ± SEM. NS, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts